Siam Wellness Group PCL

Siam Wellness Group maintains a capital structure with a debt-to-equity ratio of 0.81, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.67, suggesting limited short-term liquidity. Free cash flow is negative at -85.77 million THB, while operating cash flow stands at 535.02 million THB, indicating strong operational cash generation but significant capital expenditures. Profitability metrics show a return on equity (ROE) of 14.71% and a return on assets (ROA) of 7.24%, both above the industry median for Personal Services. The company's gross margin is 26.52% (430.41 million THB gross profit on 1.62 billion THB revenue), and operating margin is 16.47% (267.02 million THB operating income), reflecting efficient cost management and pricing power. The company's revenue is concentrated across three segments: Spa services, Sales of spa products and healthy products, and Hotel and restaurant. Spa services likely represent the largest segment, though exact revenue shares are not disclosed. The geographic exposure is primarily domestic, with operations in Chiangmai, Pattaya, Chonburi, and Samut Prakan provinces. Outlook for the current fiscal year shows a projected revenue growth of 5.3% year-over-year, with a net income growth of 3.8%. For the next fiscal year, revenue is expected to grow by 4.1%, and net income by 2.9%. These projections are supported by the company's strong operating cash flow and brand portfolio. Risk assessment indicates a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the near term. The company's capital structure and cash flow dynamics suggest a conservative approach to financing and reinvestment. Recent events include the publication of the latest financial snapshot and analyst estimates. Analysts have provided a mean price target of 4.61 THB, with a median of 4.40 THB, and a mean recommendation of 2.40 (leaning toward buy). No recent filings or transcripts have been disclosed in the provided data.